Sequentia Biotech, a #deeptech bioinformatics company focused on the analysis and application of omics data, has announced a €10 million Series A funding round, led by Seventure Partners, a leading European innovation finance firm with strong expertise in life sciences. The fundraising is accompanied by a co-investment from the EIC Fund, the European Commission’s initiative dedicated to accelerating innovative startups in the European Union.
According to Industry sources, this investment will permit Sequentia Biotech to trigger its mission of innovation in #omics, which is the collective characterization and quantification of pools of biological molecules that translate into the structure, function, and dynamics of one or more organisms. Examples of omics disciplines include genomics, transcriptomics, epigenomics, and microbiomics.
Industry sources added further that the application of omics is powering the development of more accurate diagnostic tools in biomedicine, agritech (e.g., crop protection and nutrition), and the food industry (e.g., improving food production and quality).
Walter Sanseverino, CEO and co-founder of Sequentia Biotech, welcomed the funding, saying, “ We are delighted to announce this funding round and the support we have received from Seventure Partners and the EIC Fund, two highly regarded venture capitalists with a strong track record of backing innovative life sciences companies. This investment will play a major role in advancing our mission to unlock the full potential of omics and accelerate the adoption of MICK by researchers and healthcare professionals around the world.”
The funds raised will enable Sequentia Biotech to accelerate its market introduction, optimize its flagship MICK platform, and expand its best-in-class Bioinformatics Enabling Technologies to deliver on its ambitious go-to-market strategy. The MICK platform provides cutting-edge data analysis and interpretation, enabling deeper exploration of microbiome data and translating it into actionable insights for multiple applications. This platform has the potential to redefine clinical decision-making by integrating bioinformatics intelligence around omics disciplines into medical practice, as well as biomedical and biopharmaceutical applications.
